ВЛИЯНИЕ МЕТФОРМИНА И ПИОГЛИТАЗОНА НА ФАКТОРЫ РИСКА РАЗВИТИЯ СЕРДЕЧНО-СОСУДИСТОЙ ПАТОЛОГИИ У ПАЦИЕНТОВ С САХАРНЫМ ДИАБЕТОМ 2-ГО ТИПА, УСТАНОВЛЕННЫМ ВО ВРЕМЯ СКРИНИНГА

Under assessment there was metformin and pyoglitazon effect on the risk factors of cardiovascular disease. During treatment of patients with screening-diagnosed type 2 diabetes mellitus, the following changes were noted: decreasing the levels of glycated hemoglobin, Willebrand factor and C-reactive protein, and increasing the level of HDL cholesterol. It was shown that 6-month-long therapy with metformin and pyoglItazon allowed significant improving glycemia control and influencing markers of cardiovascular risk in these patients.